Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms.

With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R and D platforms, TrilliumTM and MacropaTM, enable the development of tunable radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading.

Ratio, in collaboration with Lantheus and PharmaLogic, is currently conducting a Phase I trial to evaluate the radiation dosimetry of a novel fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers in adult healthy volunteers.

• Schusterman (Family Office)
• Duquesne (Family Office)
• PagsGroup (Family Office)
• Bristol Myers Squibb (Strategic Investment)
• Center for technology Licensing at Cornell University 

Total: $90M to date

• Close out of phase I Exploratory PK and Imaging Study
•  IND filing activities related to moving fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic into clinical trials
  

Radiopharmaceuticals

Oncology - Therapeutics
Oncology - Diagnostics